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An in vitro assay to measure 
antibody-mediated inhibition of P. 
berghei sporozoite invasion against 
P. falciparum antigens
Ana Rodríguez-Galán1,2, Ahmed M. Salman  1, Georgina Bowyer1, Katharine A. Collins1,  
Rhea J. Longley  1,4, Florian Brod  1, Marta Ulaszewska1, Katie J. Ewer  1, Chris J. Janse3, 
Shahid M. Khan3, Julius C. Hafalla2, Adrian V. S. Hill  1 & Alexandra J. Spencer  1
A large research effort is currently underway to find an effective and affordable malaria vaccine. Tools 
that enable the rapid evaluation of protective immune responses are essential to vaccine development 
as they can provide selection criteria to rank order vaccine candidates. In this study we have revisited 
the Inhibition of Sporozoite Invasion (ISI) assay to assess the ability of antibodies to inhibit sporozoite 
infection of hepatocytes. By using GFP expressing sporozoites of the rodent parasite P. berghei we are 
able to robustly quantify parasite infection of hepatocyte cell lines by flow cytometry. In conjunction 
with recently produced transgenic P. berghei parasites that express P. falciparum sporozoite antigens, 
we have been able to use this assay to measure antibody mediated inhibition of sporozoite invasion 
against one of the lead malaria antigens P. falciparum CSP. By combining chimeric rodent parasites 
expressing P. falciparum antigens and a flow cytometric readout of infection, we are able to robustly 
assess vaccine-induced antibodies, from mice, rhesus macaques and human clinical trials, for their 
functional ability to block sporozoite invasion of hepatocytes.
Although there has been an estimated 40% reduction in the incidence of P. falciparum malaria infections over the 
last 15 years, owing to the wider deployment of multiple malaria intervention strategies1, it continues to cause sig-
nificant mortality and morbidity. The WHO estimates that there were half a million malaria associated deaths in 
2014, with the majority in sub-Saharan Africa, in children under the age of 52. Reports of increasing anti-malarial 
drug resistance highlight the vital importance of a malaria vaccine.
A malaria infection in humans starts with the bite of an infected mosquito which injects P. falciparum sporo-
zoites into the skin as it takes a blood meal. Sporozoites then migrate to the liver where they infect hepatocytes 
and undergo asexual replication, subsequently leading to the formation and release of merozoites into the blood 
stream approximately 6–7 days later, which infect and re-infect red blood cells (RBCs).
Significant clinical advances have been made with two pre-erythrocytic stage recombinant vaccines against 
two different P. falciparum sporozoite stage proteins. RTS,S is an antibody inducing vaccine that targets the cir-
cumsporozoite protein (CSP)3. The other vaccine is heterologous viral vector vaccination with simian Adenovirus 
serotype 63 (ChAd63) followed by modified vaccinia Ankara (MVA), both expressing a multiple epitope (ME) 
string fused to thrombospondin related anonymous protein (TRAP) and this primarily induces effector CD8+ T 
cells against TRAP to kill infected hepatocytes, although anti-PfTRAP antibodies are also induced4. While both 
vaccines have shown some degree of efficacy in African clinical trials5,6, which was marginally enhanced (75% to 
82.4% sterile efficacy) when vaccines were combined in malaria naïve individuals7, further vaccine development 
and regimen optimisation will be required to achieve long-term efficacy in the vaccine target population.
Antibodies generated against PfCSP have been shown to block sporozoite invasion of hepatocytes8 and protec-
tion afforded by vaccination with RTS,S, a virus-like particle (VLP) expressing the repeat region and C-terminal 
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domain of CSP, correlates primarily with the level of anti-PfCSP antibodies9. In order to identify novel can-
didate vaccine antigen targets and/or different vaccine strategies, sensitive assays are required to measure the 
effect of antibodies on sporozoite survival and hepatocyte invasion. However, unlike the growth inhibition assay 
(GIA) that can be used to functionally assess vaccines against the blood-stage of malaria, there are currently no 
standardized rapid screening assays to measure the capacity of antibodies to inhibit invasion of hepatocytes by 
sporozoites. Such assays are lacking, in part due to limited access to P. falciparum sporozoites, but also the limited 
number (and availability) of P. falciparum infection-permissive hepatocyte cell lines and the lack of a medium to 
high throughput method to measure the number of infected hepatocytes.
The first study to measure the capacity of antibodies to prevent sporozoite invasion utilised a human embry-
onic lung cell line and staining for intra-cellular parasites by either Giemsa or immunofluorescence10. Following 
on from this, a number of different groups used hepatocyte cell lines to determine the capacity of antibodies 
against P. falciparum or P. vivax antigens to inhibit sporozoite infection by histological analysis11–13. While 
labelled antibodies13–15 and RT-PCR16 have been previously used as a quantitative readout of sporozoite invasion, 
these methods are labour-intensive and costly to perform.
With the advances in transgenic parasite technology it is now possible to generate chimeric P. berghei par-
asites that express P. falciparum antigens, and these parasite lines are capable of infecting mice and hepatocyte 
cell lines17. In addition, a variety of P. berghei parasites expressing fluorescent markers that can be detected by 
flow cytometry are now available. Using a transgenic P. berghei line that expresses GFP in sporozoites and during 
liver-stage infection, we recently developed an in vitro T cell killing assay and were able to demonstrate killing of 
malaria infected hepatocytes by effector CD8+ T cells (obtained from viral vector vaccinated mice) with a flow 
cytometric readout18.
In this current study, we developed a new inhibition of sporozoite invasion (ISI) assay, based on a flow cyto-
metric readout, to assess the ability of antibodies induced by immunisation, for their ability to inhibit sporozoite 
infection of hepatocytes. Using chimeric P. berghei parasites expressing the lead P. falciparum vaccine antigens, 
CSP or TRAP, we have been able to use this assay to test the function of antibodies induced in mice, primate 
and human vaccination studies. By combining the advances of chimeric parasite technology and flow cytometry 
we have established a medium to high-throughput functional assay, which can be used as an in vitro readout of 
immunisation efficacy of antibodies targeting sporozoite antigens and has scope to test many additional P. falci-
parum antigens.
Results
Optimising hepatocyte and sporozoite cell numbers for the ISI assay. For the studies described 
below two transgenic P. berghei parasite lines were used; PbGFP which expresses GFP or PbGFP-Luc which 
expresses a fusion protein of GFP and luciferase both under control of the constitutive Pbeef1α promoter. The 
chimeric P. berghei parasites expressing P. falciparum antigens (see below) also express the GFP-luciferase fusion 
protein under control of the eef1α promoter.
As different hepatocyte cell lines have different permissiveness to P. berghei sporozoite infection with vary-
ing parasite growth rates, initial experiments were performed to identify the optimal cell-culture conditions for 
the ISI assay to reliably detect differences in sporozoite infectivity by flow cytometry. In an initial experiment, 
HepG2 cells were seeded at two cell concentrations (30000 or 50000 cells per well) and infected with different 
number of PbGFP sporozoites (30000, 20000, 10000). Plates were incubated overnight prior to cell harvesting and 
acquisition of samples on the flow cytometer. Plating 30000 HepG2 per well led to higher percentages of infected 
cells compared to wells of 50000 cells (Fig. 1a) and this was consistent for any number of sporozoites added. 
Importantly, the same percentage of infected cells was achieved when the ratios of sporozoites to hepatocytes 
were compared; 30000 sporozoites and 50000 cells (1:1.6 sporozoite:cell ratio) gave a similar level of infectivity as 
30000 cells infected with 20000 sporozoites (1:1.5 sporozoite:cell ratio). The ability of different numbers of PbGFP 
sporozoites to infect Huh7 and HC04 cells was also compared. Addition of higher numbers of sporozoites led 
to an increased percentage of infected cells (Fig. 1b) for all three cell lines tested. Huh7 cells showed the highest 
permissiveness for P. berghei as a higher percentage of infected Huh7 cells was observed, compared to HepG2 
or HC04 cells, regardless of the number of sporozoites added per well (Fig. 1b). As each cell line has preferential 
cell growth medium that could affect sporozoite infectivity, we compared different combinations of cell lines and 
media to identify the optimal culture conditions. Although culturing cells in different media had only a small 
effect on the percentage of infected cells, the highest infectivity was observed with complete RPMI medium 
(Figure S1a) and therefore RPMI was used in all further experiments.
As the readout of sporozoite infectivity relies on expression of GFP from intracellular parasites and detec-
tion of this GFP signal by flow cytometry, it was important to identify the optimal time after the addition of 
sporozoites to harvest cells and acquire samples on the flow cytometer. Cells infected with PbGFP sporozoites 
could be detected by flow cytometry as early as 4 hours post infection (hpi) (Fig. 1c) which had dropped 
by 16 hours post infection, reflective of high number of transversal or aborted invasion events which can be 
detected by flow cytometry at early hours post infection19. The percentage of infected cells continued to slowly 
decline over time from 16 hours post-infection, most likely due to replication of non-infected Huh7 cells in 
the wells (Bliss et al. in preparation). Although the percentage of infected cells decreased with time, the mean 
fluorescent intensity (MFI) of the GFP signal increased, consistent with an increase in exoerythrocytic parasite 
forms within the hepatocyte20. In contrast to PbGFP infected hepatocytes, a GFP signal was not detected from 
hepatocytes infected with PbGFP-Luc sporozoites before 20 hpi (Fig. 1d), with the percentage of GFP-positive 
cells increasing after 20 hpi with a peak at 26 hpi. The reduced GFP signal intensity of PbGFP-Luc infected 
hepatocytes compared to PbGFP infected hepatocytes is due to reduced GFP-fluorescence when GFP is fused 
to luciferase21.
www.nature.com/scientificreports/
3SCIENTIFIC REpORtS | 7: 17011  | DOI:10.1038/s41598-017-17274-5
GFP MFI signal also increased over time in PbGFP-Luc infected hepatocytes, consistent with PbGFP par-
asites, indicating an increased growth of the liver stage parasite within the hepatocytes. Based on these results, 
24–28 hours after infection was chosen as the optimal time to quantify PbGFP-Luc and PbGFP infected cells by 
flow cytometry.
An anti-P. berghei CSP monoclonal antibody inhibits sporozoite invasion of hepatocytes in a 
dose dependent manner in the ISI assay. To optimise the culture and incubation periods required to 
detect antibody mediated inhibition of sporozoite invasion, initial experiments were performed with a monoclo-
nal antibody (mAb) against P. berghei CSP (3D11, mAb-PbCSP). In the first experiment we wished to determine 
whether pre-incubation of sporozoites with mAb-PbCSP for different periods of time would have an effect on 
sporozoite invasion. Addition of 1 μg/ml of mAb-PbCSP antibody was shown to reduce the percentage of infected 
cells; however no significant differences were observed in infectivity when sporozoites were directly added, or 
pre-incubated with mAb-PbCSP for 15 or 30 minutes prior to addition of the sporozoite-mAb mixture to the 
hepatocytes, in terms of the percentage of infected cells (Fig. 2a left) or when calculated as a percentage of inhibi-
tion compared to the sporozoite only wells (Fig. 2a right).
Infectivity of sporozoites is very sensitive to temperature changes. Incubation for 30 minutes at 37 oC before 
addition to hepatocytes, has been shown to reduce infectivity by 80%22, and an increase in temperature from 20 oC 
to 37 oC in the presence of serum is sufficient to induce the transformation of sporozoites into exo-erythrocytic 
forms in the absence of hepatocytes23. We therefore determined whether maintaining cells at 19–21 oC, the 
optimal temperature for P. berghei sporozoite development in mosquitoes24, improved sporozoite infectivity or 
altered the ability of mAb to block the invasion of sporozoites. Importantly we found that the incubation tem-
perature for the first hour of culture, be it 21 oC or 37 °C, did not appear to have an effect on either the infectivity 
of the cells (Fig. 2b left), or the ability of mAb-PbCSP to block sporozoite invasion (Fig. 2b right). Therefore in 
Figure 1. Optimisation of culture conditions for detection of infection P. berghei by flow cytometry. (a) 50000 
or 30000 HepG2 cells were plated per well and infected with 10000, 20000 or 30000 PbGFP sporozoites and 
harvested the following day to measure the percentage of infected cells by flow cytometry. (b) 30000 Huh7, 
HepG2 or HC04 cells were seeded per well and subsequently infected with increasing numbers of PbGFP 
sporozoites. Cells were harvested the following day and the percentage of infected cells determined by flow 
cytometry. (c) 30000 Huh7 cells per well were infected with 15000 PbGFP sporozoites and the percentage of 
infected cells was measured between 4 and 41 hours after incubation. The graph represents the percentage of 
GFP+ cells (left axis) (black line) or log Mean Fluorescence Intensity (MFI) of GFP from GFP+ cells (right axis) 
(grey line) against the time after infection. (d) 30000 Huh7 cells per well were infected with 20000 PbGFP-Luc 
sporozoites and the percentage of infected cells was measured between 20 and 48 hours after incubation. The 
graph represents the percentage of infected cells (left axis) (black line) or log Mean Fluorescence Intensity (MFI) 
of GFP in GFP+ cells (right axis) (grey line) against the time after infection.
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Figure 2. Optimising the detection of antibody mediated inhibition of sporozoite invasion. (a) 10000 PbGFP 
sporozoites were incubated with 1 μg/mL mAb-PbCSP (3D11) on ice for 0, 15 or 30 minutes prior to addition 
to 30000 Huh7 cells. Cells were harvested the following day and the percentage of GFP+ cells determined by 
flow cytometry. The graphs represent the percentage of GFP+ cells (left) or percentage of inhibition (right) 
when compared to the sporozoite only control well. (b) 20000 PbGFP sporozoites together with 1 μg/ml 
mAb-PbCSP were added to 30000 Huh7 cells and incubated at 21 oC or 37 oC for 1 hour, prior to overnight 
incubation at 37 oC. Cells were harvested the following day and the percentage of GFP+ cells determined 
by flow cytometry. Graphs represent the percentage of GFP+ cells (left) or percentage of inhibition (right) 
when mAb-PbCSP wells were compared to sporozoite only wells incubated under the same conditions. (c) 
30000 (black) or 15000 (grey) sporozoites (PbGFP-Luc) were added to 30000 Huh7 cells in the presence of a 
range of mAb-PbCSP concentrations (0–5 μg/mL) and percentage of infection measured by flow cytometry 
the following day. Graphs represent the percentage of GFP+ (left) or percentage of inhibition (right) when 
addition of mAb-PbCSP was compared to sporozoite only control wells. Data was analysed with a two-way 
ANOVA which showed a significant effect of antibody concentration but no significant effect of sporozoite 
number. (d) 15000 sporozoites (PbGFP-Luc) were added to 30000 Huh7 cells per well in the presence of 
mAb-PbCSP (0.25 or 0.5 μg/mL) and harvested at different times after infection. Graphs represent the 
percentage of GFP+ cells over time (left), percentage of inhibition (middle) or log GFP MFI of infected cells 
over time (right). The percentage of inhibition data was analysed with a two-way ANOVA to test for the effect 
www.nature.com/scientificreports/
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all further experiments serum/mAb and sporozoite were added directly to the wells, prior to centrifugation and 
incubation at 37 oC.
To determine whether inhibition of sporozoite invasion was dependent on the concentration of the mAb 
used, different mAb-PbCSP concentrations, from 0.1 to 5 μg/mL, were mixed with either 15000 or 30000 
PbGFP-Luc sporozoites. mAb-PbCSP was found to inhibit the ability of sporozoites to infect Huh7 hepatocytes 
in a concentration-dependent manner, with between 50–60% blocking at 1 μg/mL, and 96% inhibition at 5 μg/
mL (Fig. 2c left), while at 0.1 μg/mL only 3% inhibition was observed. The percentage of infected cells observed 
was doubled when infected with 30000 compared to 15000 sporozoites (Fig. 2c left), and similar drug inhibition 
curves were obtained with both 15000 and 30000 sporozoites infections. Halving the sporozoite numbers did 
not alter the dose response curve, which indicated that fewer sporozoites per well (15000) can be used without 
decreasing assay sensitivity. This would also suggest that fluctuations in sporozoite infectivity (or the error asso-
ciated with the sporozoite counts) should not impact the ISI readout, as long as the infectivity data is analyzed 
in each experiment with reference to the sporozoite infectivity in control wells. Importantly, similar inhibition 
curves were observed when either 15000 or 30000 sporozoites were added, although the percentages of inhibition 
were slightly higher when 15000 sporozoites were added (albeit not statistically significant), suggesting a potential 
limiting effect of antibody when more sporozoites are added per well.
To determine whether mAb-PbCSP was only blocking sporozoite invasion of hepatocytes or if it was 
also affecting parasite growth within the hepatocytes, PbGFP-Luc sporozoites were added in the presence of 
mAb-PbCSP at 0.25 and 0.5 μg/mL and cells harvested at different time periods to measure the number of infected 
cells and the level of the GFP signal. Although the percentage of infected cells decreased over time (Fig. 2d left), 
consistent with initial experiments, the percentage of sporozoite inhibition observed by the addition of 0.25 or 
0.5 μg/ml of mAb-PbCSP remained consistent over time (Fig. 2d middle). In addition, the level of GFP signal 
was not significantly different between the groups at any time (Fig. 2d right), consistent with the monoclonal 
antibody only blocking the ability of sporozoites to invade the hepatocytes and not affecting their subsequent 
growth within hepatocytes. While the time of readout is important in terms of the ability to detect a GFP signal by 
flow cytometry (Fig. 1), the data demonstrate the robustness of the assay, as the percentage of inhibition remains 
constant regardless of the time that cells are harvested. However due to inter experiment variability in sporozoite 
infectivity which can lead to changes in the percentage of inhibition observed (Fig. 2a,b,d), comparisons between 
groups should only be performed within a single experiment.
In addition to having established the optimal conditions to determine antigen specific inhibition, we tested the 
effect of serum concentration and heat inactivation on inhibition of sporozoite invasion. In these experiments we 
used serum collected from a naïve mouse. Increasing the concentration of serum resulted in a decreased number 
of infected cells (Figure S1b left) and therefore increased percentage of inhibition (Figure S1b middle). Heat inac-
tivation appeared to increase inhibition of sporozoite invasion (albeit not statistically significantly), although it 
is unlikely that this is antibody mediated inhibition as heat inactivation of mAb-PbCSP abolished its sporozoite 
inhibitory effect (Figure S1b right). The increased inhibition of sporozoite invasion observed with increasing 
serum concentrations is most likely due to the role of serum, and culture temperature, in inducing transformation 
of sporozoites into exo-erythrocytic forms23, thereby reducing sporozoite infectivity. Given the increased inhibi-
tion of sporozoite invasion, or decreased sporozoite infectivity, observed with increasing serum concentrations 
and the variability that can occur between experiments, it is important to include controls with pre-vaccination 
or naïve serum in all experiments, to ensure inhibition is antigen specific.
The ISI assay using antibodies induced by vaccination with vectored vaccines expressing 
PfCSP. Having optimized the ISI assay, we wished to use it to test the inhibitory effect of antibodies against 
CSP of the human parasite P. falciparum. For these experiments we used a chimeric P. berghei line that has 
the endogenous csp gene replaced with the P. falciparum csp gene (called PfCSP@PbCSP). Sporozoites of this 
chimeric line expresses only P. falciparum CSP (PfCSP) and it produces normal numbers of sporozoites that 
have similar infectivity to HepG2 as wild type P. berghei sporozoites (Triller G, Scally SW et al., submitted). 
We first tested inhibition of invasion of PfCSP@PbCSP sporozoites by the anti-PfCSP mAb 2A10 and a clear 
dose effect was observed when increasing concentrations of 2A10 were used (Fig. 3a left). We also tested the 
ability of anti-PfCSP 2A10 monoclonal antibody to inhibit P. berghei parasites expressing the PfCSP gene when 
expressed as an additional gene under the control of the PbUIS4 promoter (PfCSP@PbUIS4). Despite the ability 
of anti-PbCSP 3D11 monoclonal antibody to inhibit invasion (Figure S2b), to our surprise, increasing concentra-
tions of the PfCSP specific monoclonal antibody 2A10 were unable to inhibit invasion when parasites expressed 
both copies of the CSP protein, and it was only in the presence of PbCSP specific mAb 3D11 when inhibition was 
observed (Fig. 3a right). Interestingly, 2A10 monoclonal antibody is able to bind to the sporozoite surface of both 
PfCSP@PbCSP and PfCSP@PbUIS4 (Figure S2a), even though inhibition against PfCSP@PbCSP in the ISI assay 
is not observed (Figure S2b). When serum samples from PfCSP vaccinated mice were used to compare inhibition 
observed with each parasite line, although some degree of inhibition with both parasites lines was observed, 
significant inhibition above the naïve samples was more apparent with the replacement PfCSP@PbCSP (Fig. 3b). 
Given the critical role of CSP in cell invasion, we hypothesized that in conditions of high anti-PfCSP antibodies, 
parasites may revert to invasion of hepatocytes through PbCSP and that this may be antibody dose dependant.
To determine whether the differences in inhibition observed with the different parasites strains was related 
to antibody titre, serum samples showing a range of antibody titres, due to different recombinant vaccine (viral 
of antibody concentration over time, no significant effect of time was observed. Log (MFI GFP+) data was 
analysed with a two-way ANOVA and post-hoc Dunn’s multiple comparisons test, but no difference between 
groups at each timepoint was observed.
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vector vs VLP) or viral vectored vaccine dose, were then tested against both parasite lines (although often in 
separate experiments due to parasite availability). Consistent with previous experiments, inhibition was observed 
against both the PfCSP@PbCSP and PfCSP@PbUIS4 parasites with serum from mice vaccinated with a sim-
ian adenovirus serotype 63 (ChAd63) expressing CSP followed at least 6 weeks later by a boost vaccination of 
modified vaccinia Ankara (MVA) expressing PfCSP (ChAd63-MVA PfCSP) (Fig. 4a left, Fig. 4b left). However 
when mice were vaccinated with a VLP expressing PfCSP, known as R21, which induces high titres of anti-PfCSP 
antibodies25, no inhibition of invasion of PfCSP@PbUIS4 parasites was observed (Fig. 4b left, Figure S3a). In 
contrast a high level of inhibition of the replacement PfCSP@PbCSP parasites was observed with the same serum 
samples, even at low serum dilutions (Fig. 4a left) and a positive correlation was observed between antibody 
titre and inhibition when replacement PfCSP@PbCSP parasites were used in the assay (Fig. 4a right). In con-
trast, a negative correlation between percentage inhibition and antibody titre was observed when the addition 
Figure 3. Inhibition of PfCSP@PbCSP and PfCSP@PbUIS4 parasites with monoclonal antibodies. (a) 15000 
sporozoites PfCSP replacement (PfCSP@PbCSP) (left) or PfCSP addition (PfCSP@PbUIS4) (right) were added 
to 30000 Huh7 cells with increasing concentrations of mAb-PfCSP (2A10), with the addition of mAb-PbCSP 
(3D11) at 1 μg/mL for PfCSP addition parasites (grey squares). Cells were harvested 24 to 28 hours later and 
the percentage of infected cells determined by flow cytometry. Graphs represent the percentage of inhibition 
relative to sporozoite only control wells, calculated for each replicate at each dose. (b) 20000 Huh7 cells per well 
were cultured overnight prior to the addition of either 10000 PfCSP@PbCSP or PfCSP@PbUIS4 sporozoites 
together with serum samples from ChAd63-MVA vaccinated mice (5% final concentration of serum) (in a 
separate experiment from Fig. 4). Cells were harvested 24 to 28 hours later and the percentage of infected cells 
determined by flow cytometry. Graphs represent the frequency of GFP + cells (left), percentage of inhibition 
(middle) against each parasite strain or when comparing the same serum sample tested with either cell line 
(right). Grey bars denote the percentage of inhibition observed in the assay with naïve serum samples.
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parasites PfCSP@PbUIS4 were used in the assay (Fig. 4b right). The effect was not experiment dependant, as a 
significant correlation was observed when only a small number of samples were tested together in a single exper-
iment (Figure S3a right). Importantly the inhibition observed in this assay was shown to be antigen specific, as 
serum samples simultaneously tested against PfCSP@PbCSP, PfCSP@PbUIS4 or GFP parasites, inhibition was 
only observed against PfCSP@PbCSP parasites (Figure S3b). In addition, serum from mice vaccinated with a 
Figure 4. Inhibition of PfCSP@PbCSP and PfCSP@PbUIS4 parasites with PfCSP vaccinated serum samples. 
(a) In 3 separate experiments, serum from BALB/c mice vaccinated with 107 iu ChAd63.PfCSP 106 MVA.PfCSP 
(filled circle), 108 iu ChAd63.PfCSP 107 pfu MVA.PfCSP (closed squares) or 3 μg R21 in Matrix M (filled 
triangles) were tested for the ability to inhibit the invasion of Huh7 cells with PfCSP@PbCSP sporozoites. In 
each experiment, the grey bars denote the level of inhibition observed with naïve serum samples. Data in each 
graph was analysed with a two-way ANOVA and post-hoc Sidaks multiple comparison, asterisk denote the 
level of significance comparing PfCSP samples against naïve serum samples, *p < 0.05 ****p < 0.0001. The 
percentage of inhibition observed with 2% serum concentration was compared to antibody titres measured 
by ELISA (right) and analysed with a two-tailed Spearmans correlation. (b) In 3 separate experiments, serum 
from BALB/c mice vaccinated with 107 iu ChAd63.CSP 106 MVA.CSP (filled circle), 108 iu ChAd63.CSP 107 
pfu MVA.CSP (closed squares) or 3 μg R21 in Matrix M (filled triangles) were tested for the ability to inhibit 
the invasion of Huh7 cells with PfCSP@PbUIS4 sporozoites. In each experiment, the grey bars denote the level 
of inhibition observed with naïve serum samples. Data in each graph was analysed with a two-way ANOVA 
and post-hoc Sidaks multiple comparison, asterisk denote the level of significance comparing PfCSP samples 
against naïve serum samples, *p < 0.05 ****p < 0.0001. The percentage of inhibition observed with 2% serum 
dilutions was compared to antibody titres measured by ELISA (right) and analysed with a two-tailed Spearmans 
correlation (p = 0.0318). (c) Serum samples from human volunteers vaccinated with a ChAd63.PfCSP followed 
by MVA.PfCSP were tested for the ability to inhibit the invasion of Huh7 cells with PfCSP@PbCSP sporozoites. 
Pre-vaccination (circle) and 2 to 3 week post MVA boost (square) boost serum samples were tested at 10% and 
20% serum concentrations (left) and the percentage of inhibition observed with 10% serum concentrations 
was compared to the level of PfCSP specific antibodies measured by ELISA (right) with data analysed with a 
non-parametric Spearmans test, but no significant correlation was observed. (d) Serum samples from human 
volunteers vaccinated with a ChAd63.PfCSP followed by MVA.PfCSP were tested for the ability to inhibit the 
invasion of Huh7 cells with PfCSP@PbUIS4 sporozoites. Pre-vaccination (circle) and 2 to 3 week post MVA 
boost (square) boost serum samples were tested at 2% and 10% serum concentrations (left) and the percentage 
of inhibition observed with 10% serum concentrations was compared to the level of PfCSP specific antibodies 
measured by ELISA (right) with data analysed with a non-parametric Spearmens test, but no significant 
correlation was observed.
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different P. falciparum antigen (UIS3) did not show any inhibition against PfCSP@PbCSP or PfCSP@PbUIS4 
parasites (Figure S3c).
Serum samples from human volunteers vaccinated with ChAd63-MVA expressing PfCSP were also assessed 
for their ability to inhibit invasion of both PfCSP expressing parasites into hepatocyte cell lines. When serum sam-
ples were tested for inhibition of the replacement parasite PfCSP@PbCSP, a significant increase post-vaccination 
was only observed with the 10% serum dilutions (Fig. 4c left) and a positive trend (albeit not statistically signifi-
cant) towards an increase in inhibition with higher anti-PfCSP antibodies was also observed (Fig. 4c right). When 
serum was tested for inhibition of the additional copy parasites PbCSP@PbUIS4, an increase in the percentage 
of inhibition was observed between the pre-vaccination and post-vaccination samples, but was only statistically 
significant at the 10% serum dilutions (Fig. 4d left), and a significant correlation between the level of anti-PfCSP 
antibodies and inhibition was also observed (Fig. 4d right).
The ISI assay using antibodies induced by vaccination with viral vectors expressing 
PfTRAP. Having observed PfCSP specific inhibition of PfCSP expressing sporozoites with serum from 
viral-vector vaccinated individuals, we wished to test for the ability to inhibit sporozoite invasion of P. berghei 
sporozoites expressing other P. falciparum antigens. Although CD8+ T cells have been shown to play the major 
role in TRAP specific protection in both mice and humans26–29, vaccination with ChAd63-MVA has been shown 
to induce anti-PfTRAP antibodies in mice, macaques and humans4,30, in addition to high frequencies of CD8+ 
T cells. To determine whether inhibition could be observed across species in the ISI assay with an additional 
P. falciparum antigen, we tested serum samples from ChAd63-MVA PfTRAP vaccinated mice, macaque and 
humans, for the ability to inhibit PfTRAP expressing P. berghei chimeric parasites. Given inhibition against 
PfCSP@PbUIS4 was observed with samples from ChAd63-MVA vaccinated mice and binding of serum from 
ChAd63-MVA ChAd63 PfTRAP vaccinated mice to the surface of chimeric parasites has been shown31, we were 
confident that PfTRAP expression on the parasites would be high enough to observe inhibition in this assay.
Serum samples were obtained from C57BL/6 and CD-1 mice vaccinated with a heterologous ChAd63-MVA 
vaccination regimen of vectors expressing the lead liver-stage malaria antigen ME-TRAP, which had previously 
been shown to induce high titres of anti-PfTRAP antibodies30. Although a small increase in the percentage of 
sporozoite inhibition was observed at 2% serum concentrations, we only observed a significant increase in inhibi-
tion, above the level of observed with P. berghei sporozoites in which PbTRAP had been deleted, with CD1 serum 
samples at a 10% serum concentration (Fig. 5a left). In a separate experiment, serum samples from ChAd63-MVA 
PfTRAP vaccinated BALB/c mice were tested at a final concentration of 2, 5 or 10% serum. While the highest 
level of inhibition was observed with 10% serum, sporozoite inhibition was observed at both lower serum con-
centrations (Fig. 5a middle). Importantly, serum from mice vaccinated with an alternative P. falciparum antigen, 
UIS3, showed no inhibition against PfTRAP@PbUIS4 parasites (Fig. 5a middle). The ability of serum to block 
sporozoite invasion did not appear to be related to the strain of mice or vaccine insert (ME-TRAP vs TRAP), 
but the level of antibodies induced by vaccination, as a significant correlation between antibody ELISA titre and 
percentage inhibition was observed (Fig. 5a right).
Mouse serum samples were also tested against a chimeric P. berghei line that has the endogenous trap gene 
replaced with the P. falciparum trap gene (called PfTRAP@PbTRAP). Sporozoites of this line only express P. 
falciparum TRAP (PfTRAP) and it produces normal number of sporozoites and infectivity in mice (Salman et al., 
manuscript in preparation). Consistent with PfTRAP@PbUIS4 parasites, no significant inhibition above back-
ground (naïve BALB/c serum) with 2% serum from C57BL/6 or CD1 mice was observed, while pooled CD1 
serum tested at 5% dilution and 2% serum from BALB/c mice showed significant inhibition above background 
(Fig. 5b left). Importantly the inhibition against PfTRAP@PbTRAP was shown to be antigen specific, as mice 
vaccinated with an alternative P. falciparum antigen, UIS3, did not show inhibition above background, nor did 
PfTRAP vaccinated serum samples show inhibition against P. berghei sporozoites expressing only GFP (Fig. 5b 
middle). In addition, the percentage of inhibition observed in this assay was shown to correlate with PfTRAP 
antibodies levels (Fig. 5b right).
Serum samples from ChAd63-MVA ME-TRAP vaccinated rhesus macaques30 and human volunteers32 were 
also tested for their ability to inhibit PfTRAP@PbUIS4 sporozoites. However, high levels of inhibition observed 
with the pre-vaccination samples made it difficult to observe a clear effect of vaccination with either the macaque 
(Fig. 5c) or human (Fig. 5d) serum samples. A small but significant difference between pre and post-vaccination 
serum samples was observed for macaque samples at 10% dilution (Fig. 5c middle), but not 2% serum dilution 
(Fig. 5c left), and there was no significant correlation between PfTRAP antibodies levels and the percentage 
of inhibition (Fig. 5c right). Due to the low-level inhibition and high background observed with serum from 
macaques and humans, we chose not to test samples against PfTRAP@PbTRAP sporozoites. Given the low titres 
of antibodies observed against PfTRAP, it would suggest antibody titres need to be above a threshold to observe 
an antigen specific effect in the ISI assay.
Discussion
A versatile, robust and relative-high throughput in vitro functional assessment of antibody-mediated inhibition of 
P. falciparum sporozoite invasion of hepatocytes is still lacking. In this study we have made use of recent advances 
in transgenic P. berghei technology to develop a robust in vitro inhibition of sporozoite invasion (ISI) assay for 
the functional assessment of antibodies against P. falciparum antigens. By utilising fluorescent/luminescent P. 
berghei parasite that express P. falciparum antigens, we can circumvent the challenges conducting experiments 
with P. falciparum sporozoites, such as the paucity of cell lines that are permissible infection and the lack of suita-
ble reporter P. falciparum lines that can be used to rapidly quantify parasite development in infected hepatocytes 
(i.e. by flow cytometry).
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Figure 5. Inhibition of PbPfTRAP sporozoite invasion with serum from PfTRAP vaccinated mice, macaques 
and humans. (a) C57BL/6, CD-1 or BALB/c mice immunised with 108 iu ChAd63-PfTRAP and boosted with 
106 pfu MVA-PfTRAP (C57BL/6 or CD-1) or 107 pfu MVA-PfTRAP (BALB/c) at least 6 weeks later, with serum 
harvested approximately 2 weeks after the MVA boost. In a separate experiment, BALB/c mice vaccinated 
with 108 iu ChAd63-PfUIS3 and boosted with 107 pfu MVA-PfUIS3 were used as an irrelevant antigen control 
(middle). Huh7 cells were infected with PfTRAP@PbUIS4 sporozoites mixed with increasing concentrations 
of serum prior to harvesting cells to determine P. berghei infectivity by flow cytometry 24 to 28 hours later. 
Graphs represent the percentage of inhibition observed with serum samples from C57BL/6 and CD-1 (left) 
or BALB/c (middle) vaccinated mice, grey bars denote the level of inhibition observed with naïve serum or 
inhibition observed against P. berghei that does not express PbTRAP (left). Data in each graph was analysed 
with a two-way ANOVA and post-hoc Sidaks multiple comparison, asterisk denote the level of significance 
comparing PfTRAP samples against naïve serum samples, *p < 0.05, ***p < 0.001, ****p < 0.0001. Inhibition 
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Having identified the optimal cell lines, culture conditions and flow acquisition time-points, we employed the 
ISI assay to test the inhibitory effect of antibodies against P. falciparum CSP using chimeric P. berghei parasites 
expressing P. falciparum CSP. CSP is the most abundant antigen expressed on the surface of sporozoites and the 
basis of the RTS,S vaccine. RTS,S is a VLP based vaccine that consists of a repeat and T-cell epitope containing 
regions of PfCSP fused to hepatitis B surface antigen and protection after vaccination with RTS,S in combina-
tion with the adjuvant AS01 has been shown to correlate with vaccine induced anti-PfCSP antibody levels9. In 
this study, we used two chimeric parasites; one in which the endogenous csp gene has been replaced with the P. 
falciparum csp gene (’replacement’ chimeric parasites). The other line has the P. falciparum csp gene expressed 
under the control of liver-stage promoter UIS4 and therefore in this line both P. berghei and P. falciparum CSP are 
expressed in sporozoites. Such ‘additional copy’ chimeric parasites expressing P. falciparum proteins have been 
used to analyse protective immunity, in vivo, in mice that have been immunized with vaccines directed against 
the corresponding P. falciparum antigens31. Specifically, in the case where a P. falciparum antigen does not have a 
P. berghei homolog, the only option for generation of a chimeric P. berghei is to express the P. falciparum antigen 
as an additional copy31.
Preliminary experiments, comparing protection after challenge of immunized mice with 3 different antigens 
with either ‘additional copy’ or ‘replacement’ chimeric parasites revealed the same levels of protection (Salman, 
unpublished results). In our ISI assay we observed differences in inhibition of invasion of hepatocytes using 
sporozoites of either additional copy or replacement parasites. Using serum from mice and humans vaccinated 
with ChAd63-MVA vectors expressing PfCSP, we observed inhibition of sporozoite invasion with both the addi-
tional copy and replacement chimeric sporozoites. Interestingly, when using the additional copy chimeric sporo-
zoites, an inverse relationship between the level of anti-PfCSP antibodies and sporozoite invasion was observed. 
CSP is a critical protein, which once proteolytically cleaved is involved in essential steps involved in host-cell 
invasion. In the presence of cleavage inhibitors sporozoites are unable to invade hepatocytes33. The inverse corre-
lation between antibody titre and invasion observed with the additional copy chimeric sporozoites suggests that 
in conditions of high anti-PfCSP antibodies, where blocking of sporozoite invasion would be mediated by block-
ing PfCSP protein cleavage, parasites can use PbCSP-mediated invasion of hepatocytes. This increasing lack of 
inhibition observed with additional copy chimeric sporozoites was observed with both the monoclonal antibody 
against P. falciparum CSP (Fig. 4a) and with serum samples from mice vaccinated with a PfCSP-expressing VLP, 
which induces the highest levels of anti-PfCSP antibodies. In contrast, a significant positive correlation between 
antibody titre and the level of sporozoite invasion was observed with the replacement sporozoites which only 
express PfCSP (Fig. 4a). A possible explanation why protection is observed in vivo after challenge of immunized 
mice with sporozoites of the additional copy chimeric parasites25 is that in vivo protection can be dependent on 
multiple factors, such as neutralising sporozoites, opsonisation or reducing growth within the hepatocyte34. It is 
important to note that since PbUIS4 drives P. falciparum antigen expression in the additional copy parasites and 
it is one of the most abundant mRNA transcripts present in salivary gland sporozoites35–37, it is likely that the level 
of P. falciparum antigen expression in addition parasites will be higher than the P. berghei homolog or observed 
with the natural promoter in P. falciparum sporozoites. It is therefore possible that performing the ISI assay with 
addition parasites may show greater levels of inhibition that would be observed with replacement P. berghei 
chimeric or P. falciparum sporozoites. Given the inverse relationship between antibody titre and inhibition of 
invasion observed with additional copy vs replacement chimeric PfCSP sporozoites, in addition to the likelihood 
that there will be overexpression of the P. falciparum antigen in addition parasites, it will be essential, where 
of 2% serum samples plotted against the level of PfTRAP specific antibodies measured by endpoint ELISA 
(right) with data analysed with a Spearmans non-parametric correlation test, a significant positive correlation 
was observed (p = 0.0005). (b) C57BL/6, CD-1 or BALB/c mice immunised with 108 iu ChAd63-PfTRAP and 
boosted with 106 pfu MVA-PfTRAP (C57BL/6 or CD-1) or 107 pfu MVA-PfTRAP (BALB/c) at least 6 weeks 
later, with serum harvested approximately 2 weeks after the MVA boost. BALB/c mice vaccinated with 108 iu 
ChAd63-PfUIS3 and boosted with 107 pfu MVA-PfUIS3 were used as an irrelevant antigen control (middle). 
Huh7 cells were infected with PfTRAP@PbUIS4 or GFP only (middle) sporozoites and cells harvested between 
24 and 28 hours later to determine P. berghei infectivity by flow cytometry. Graphs represent the percentage of 
inhibition observed with serum samples from C57BL/6 and CD-1 or BALB/c (left) vaccinated mice, grey bars 
denote the level of inhibition observed with naïve serum. Inhibition of 2% serum samples plotted against the 
level of PfTRAP specific antibodies measured by endpoint ELISA (right) with data analysed with a Spearmans 
non-parametric correlation test, a significant positive correlation was observed (p = 0.0004). Data in each graph 
was analysed with a two-way ANOVA and post-hoc Sidaks multiple comparison, asterisk denote the level of 
significance comparing PfTRAP samples against naïve serum samples, *p < 0.05, ***p < 0.001. (c) Rhesus 
macaques were vaccinated with ChAd63.ME-TRAP followed 8 weeks later by an MVA.ME-TRAP boost were 
tested for the ability to inhibit invasion of Huh7 cells by PfTRAP@PbUIS4 sporozoites in the standard ISI 
assay. Pre-vaccination (circle) and 3 week post-MVA boost (square) serum samples were tested at 2% (left) and 
10% (middle) serum dilutions, with % inhibition of 10% serum samples (right) compared to the level of post-
vaccination TRAP specific antibodies measured by ELISA (right). Data was analysed with a non-parametric 
Spearmans correlation test, but no significant correlation was observed. (d) Serum samples from human 
volunteers vaccinated with a ChAd63.ME-TRAP followed by MVA.ME-TRAP were tested in the ISI assay for 
the ability to inhibit the invasion of Huh7 cells with PfTRAP@PbUIS4 sporozoites. Pre-vaccination (circle) and 
2 to 3 week post MVA boost (square) boost serum samples were tested at 10% (left) and 20% (middle) serum 
concentrations and the percentage of inhibition compared to the level of TRAP specific antibodies measured 
by ELISA (right) with data analysed with a non-parametric Spearmans test, but no significant correlation was 
observed.
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possible, to use replacement chimeric sporozoites in future ISI assays, particularly where the vaccination regimen 
is capable of inducing high titre antibodies.
Humanised mice, specifically those with livers engrafted with human hepatocytes, have been used to analyse 
inhibition of P. falciparum sporozoite invasion of hepatocytes, both using anti-PfCSP monoclonal antibodies38 
and with sera from human volunteers immunized after infection with sporozoites, by mosquito bites, and treated 
with chloroquine (DAP)39. However these experiments are expensive and laborious, primarily due to the pur-
chase cost of the humanised mice or time and staffing required to maintain and engraft humanised mice in house, 
and this very much limits their use in screening large numbers of serum samples. With the ability to generate 
chimeric P. berghei sporozoites that express P. falciparum31 and P. vivax40 antigens as either replacement or addi-
tional copies17, the ISI assay as described here can be used to rapidly test serum from human clinical vaccine trials 
and other pre-clinical vaccine studies where humans and animals have been vaccinated with different human 
malaria vaccines.
Although viral-vectored vaccines have been used primarily for the induction of high levels of CD8+ T cells 
against the liver-stage of malaria, heterologous prime-boost vaccination with ChAd63 followed by MVA also 
induces strong antibodies responses41. Therefore we tested serum samples from mice, rhesus macaques and 
humans that had been vaccinated with these viral vectors expressing either PfCSP or PfTRAP to analyse inhibi-
tion of invasion of P. berghei sporozoites expressing either PfCSP or PfTRAP. Serum samples from mice vacci-
nated with either ChAd63-MVA PfCSP or PfTRAP both displayed inhibition against the corresponding chimeric 
P. berghei parasites, and inhibition correlated with the level of anti-PfCSP or anti-PfTRAP antibodies. However 
the level of antibodies induced in macaques and humans with ChAd63-MVA PfTRAP vaccination was too low 
to observe an inhibitory effect on sporozoite invasion and only a small inhibitory effect was observed when 
using human serum after ChAd63-MVA PfCSP vaccination. Due to the low-level of inhibition observed with 
PfTRAP@PbUIS4 parasites, where PfTRAP would likely be over-expressed and potentially give higher levels 
of inhibition, we chose not to test these same samples with PfTRAP@PbTRAP when they became available. 
Antibodies induced by immunisation with ChAd63-MVA expressing PfCSP are known to be lower than induced 
by vaccination with RTS,S32, and this would most likely explain why we observed significant increase in ISI inhi-
bition when we used serum samples from mice vaccinated with the other, more recently described, PfCSP VLP 
vaccine, R2125. Therefore, it will be of great interest to use the ISI assay to directly compare the inhibitory capacity 
of serum collected from either RTS,S or R21 vaccinated individuals in future clinical trials.
The low level inhibition observed with low titre serum samples (macaques, human and PfTRAP vaccinated 
C57BL/6 and CD1 mice) highlights the need to include pre-vaccination or naïve serum controls in each test to 
ensure inhibition is specific. This is particularly true as the higher the quantity of serum in the assay, the greater 
the non-specific effect of serum. In addition, varying levels of inhibition seen with naïve serum in different exper-
iments may suggest serum quality could affect the assay readout, although this has not formally been tested in 
this study. Despite the background inhibition observed in this assay, the data clearly shows that when strong 
inhibition is observed, the inhibition is antigen specific, as we do not observe inhibition with irrelevant antigens, 
nor was inhibition against wild-type P. berghei parasites observed with PfTRAP and PfCSP serum samples. This 
however will not always be the case, particularly when P. falciparum antigens have reported cross species reac-
tivity, for example P. falciparum CelTOS42. In these instances it will be important to use replacement parasites to 
limit the cross species effect.
In this study we have developed a robust in vitro ISI assay by making use of the advances in transgenic P. 
berghei parasite technology, that can be used to functionally assess the invasion inhibitory capacity of antibodies 
against P. falciparum antigens. Until such time that brightly fluorescent P. falciparum sporozoites and, impor-
tantly, a permissive (preferably immortalised) human hepatocyte cell line becomes readily available, this in vitro 
ISI assay should prove to be a valuable addition to the toolkit of assays to functionally assess vaccine induced 
antibodies against P. falciparum antigens.
Materials and Methods
Ethics statement. All animal work was conducted in accordance with the UK Animals (Scientific 
Procedures) Act 1986 and approved by the University of Oxford Animal Care and Ethical Review Committee for 
use under Project License 30/2889 and P9804B4F1. Animals were group housed in individually ventilated cages 
under specific pathogen free conditions, with constant temperature, humidity and with a 12:12 light-dark cycle 
(8am to 8 pm). For induction of short-term anaesthesia, animals were either injected intramuscularly (i.m.) with 
xylazine and ketamine or anaesthetized using vaporized IsoFlo®. All animals were humanely sacrificed at the end 
of each experiment by an approved Schedule 1 method. All efforts were made to minimize suffering.
Rhesus macaque serum samples were obtained from an immunogenicity study measuring the improved 
immunogenicity of ChAd63-MVA ME-TRAP by fusion to human MHC Class II invariant chain30. Ethical 
approval was granted by the University of Wisconsin-Madison IACUC (termed Animal Care and Use Committee) 
and granted protocol number g00677.
Human serum samples used in this study were obtained from a Phase IIa efficacy study in which individ-
uals were vaccinated with ChAd63-MVA expressing ME-TRAP or PfCSP prior to controlled human malaria 
challenge (CHMI) with P. falciparum infected mosquitoes32. The study was conducted at the Centre for Clinical 
Vaccinology and Tropical Medicine, University of Oxford (Oxford, United Kingdom), and at the National Institute 
for Health Research (NIHR) Wellcome Trust Clinical Research Facility, part of the University of Southampton 
and University Hospital Southampton National Health Service (NHS) Foundation Trust (Southampton, United 
Kingdom). Healthy, malaria-naive men and non-pregnant women aged 18–45 years were invited to partici-
pate in the study. All volunteers gave written informed consent prior to participation, and the study was con-
ducted according to the principles of the Declaration of Helsinki and in accordance with good clinical practice. 
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All necessary approvals for the study were granted by the United Kingdom National Research Ethics Service, 
Committee South Central–Oxford A (reference 12/SC/0037), and the United Kingdom Medicines and Healthcare 
Products Regulatory Agency (reference 21584/0293/001-0001). The trial was registered with Clinical-Trials.gov 
(referenceNCT01623557).
Vaccines and Vaccinations. Female BALB/cOlaHsd (BALB/c), C57BL/6JOlaHsd (C57BL/6) or ICR 
(CD1) mice 6 weeks of age or older (Envigo, UK) were immunized intramuscularly with chimpanzee adenovi-
rus 63 (ChAd63) expressing the relevant antigen, followed at least 6 weeks later with an intramuscular injection 
of modified Ankara Virus (MVA) expressing the relevant antigen. All vaccines were produced and titred as 
previously described43. To induce high titre antibodies against P. falciparum CSP, BALB/c mice received 2 doses 
of 3 μg of a virus-like particle expressing the repeat region and C-terminal domain of PfCSP (R21)25 mixed with 
12 μg of adjuvant Matrix M 4 weeks apart with serum harvested 2 weeks after the final vaccination. Antibody 
responses against either PfTRAP or PfCSP were measured by ELISA, with plates coated with PfTRAP protein 
or a synthetic peptide (Eurogentec) based on the repeat region of the PfCSP with the amino acid sequence 
PfCSP(NANP)6C32.
3D11 (anti-PbCSP monoclonal antibody) and 2A10 (anti-PfCSP monoclonal antibody) hybridomas, obtained 
from MR4 or BEI resources, were grown in house and supernatant purified over a protein A column following 
standard technique. Only a Fab preparation of 3D11 was available at the time of optimisation experiments, how-
ever it gave comparable results to full length 3D11 mAb when the two preparations were later directly compared 
(data not shown).
Hepatocyte Cell Lines. HepG2 (ATCC), Huh7 and HC04 (ATCC) hepatocyte cell lines were propagated 
in DMEM (Dulbecco’s Modified Eagle’s Medium) or RPMI-1640 supplemented with 10% heat inactivated FCS, 
100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine (all reagents obtained from Sigma Aldrich). 
Cells were cultured at 37 oC and 5% CO2 with the addition of TrypLE Express Enzyme (Life Technologies) to aid 
in detachment of cells from culture plates or flasks. Typically 30000 cells were seeded on a 96 well-flat bottom 
plate at least 6 hours prior to sporozoite addition.
Parasite Preparation. Plasmodium berghei sporozoites expressing GFP under the control of the EF1a 
promoter (PbANKA-GFPPbeef1a, line 507cl1, called PbGFP)44, GFP-luciferase (PbANKA-GFP::LucPbeef1a_230p, 
line 507cl1, called PbGFP-Luc), GFP-luciferase and PfCSP under the control of the P. berghei CSP promoter 
(PbANKA-PfCSP(r)PbCSP; line 2257cl2, called PfCSP@PbCSP), PfTRAP under the control of the P. berghei TRAP 
promoter (PbANKA-PfTRAP(r)PbTRAP; line 2632 cl1, called PfTRAP@PbTRAP) (Salman in preparation) or 
GFP-luciferase and P. falciparum antigens under the control of the UIS4 promoter31 (PfCSPPbuis4 GFP::LucPbeef1a_230p, 
line 2243cl3, called PfCSP@PbUIS4; PfTRAPPbuis4 GFP::LucPbeef1a_230p, line 2281cl1, called PfTRAP@PbUIS4) were 
isolated from female Anopheles stephensi mosquitoes around 21 days after feeding on P. berghei blood stage 
infected donor mouse. To improve sporozoite yields, mosquitoes were fed on a naïve mouse 7 days after the first 
feed. Salivary glands from infected mosquitoes were manually dissected and kept on ice, with homogenisation 
and counting sporozoites under phase contrast microscopy performed just prior to plating to maintain sporozoite 
infectivity. Sporozoites (typically 15000 per well) were mixed on ice with serum samples or monoclonal antibody 
diluted in medium. For addition of sporozoite to hepatocyte cell lines, culture medium was removed and replaced 
with mAb/serum and sporozoite mixture (final volume 100μl), prior to centrifugation of the plates at 500 g for 
5 minutes to enhance sporozoite entry into hepatocytes18 and incubation at 37 oC.
Assessment of infectivity by flow cytometry. Cells were harvested after overnight incuba-
tion when using PbGFP, or at least 24 hours after addition of sporozoites when using PbGFP-Luc sporo-
zoites. Typically culture medium was removed from each well and 30 µL of trypsin (TrypLE Express 
Enzyme, Life Technologies) added and incubated for 10–15 minutes, prior to resuspension in 1%BSA (10% 
Fetal Calf Serum) in PBS and transferred to a FACS tube or to a 96-well U bottom plate for acquisition. 
4′,6-diamidino-2-phenylindole dihydrochloride (DAPI, final concentration 1 μg/ml, Sigma Aldrich) was 
added just prior to acquisition for the exclusion of dead cells. Samples were acquired with a LSR IITM flow 
cytometer (BD Biosciences) using FACSDIVATM software V 6.2 (BD Biosciences). P. berghei infected cells 
were identified by gating on viability and size, removing doublets and gating on GFP positive but PE (auto-
fluorescene) negative cells (Figure S3).
Statistical analysis. Cytometer acquisitions files (.fcs) were analysed with FlowJo.V 9.7.6 (Tree Star). The 
percentage of sporozoite inhibition was calculated as a reduction in the percentage of infected cells observed in 
untreated wells (average) compared to the percentage of infected cells observed in the presence of serum/mAb.
Graphs and statistical analysis was performed using GraphPad Prism 6.0. A potential correlation between two 
parameters was evaluated using a nonparametric Spearman correlation. When comparing the percentage inhibi-
tion between groups, Kruskal-Wallis test with Dunn’s multiple comparisons test were used. To evaluate whether 
there was an effect of vaccination in macaque and human samples, blocking values pre- and post-vaccination 
(paired data) were analysed with a Wilcoxon matched-pairs signed rank test (two tailed). P-values lower than 0.05 
were considered to be significant. To determine if there was a specific effect of mouse serum compared to naïve 
controls at different serum dilutions or from different vaccination regimens, data was analysed with a two-way 
ANOVA and post-hoc Sidaks multiple comparison test.
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